← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

OptimizeRx Corporation (OPRX) 10-Year Financial Performance & Capital Metrics

OPRX • • Industrial / General
HealthcareHealthcare ITLife Sciences TechnologyPharmaceutical Commercialization
AboutOptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.Show more
  • Revenue $92M +28.8%
  • EBITDA -$9M +60.9%
  • Net Income -$20M -14.5%
  • EPS (Diluted) -1.10 -6.8%
  • Gross Margin 64.45% +7.5%
  • EBITDA Margin -10.18% +69.7%
  • Operating Margin -14.88% +59.7%
  • Net Margin -21.83% +11.1%
  • ROE -16.51% -18.8%
  • ROIC -7.18% +53.3%
  • Debt/Equity 0.28 -2.5%
  • Interest Coverage -2.23 +87.7%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 30.2%

✗Weaknesses

  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y30.35%
5Y30.23%
3Y14.55%
TTM24.18%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM100.14%

EPS CAGR

10Y-
5Y-
3Y-
TTM100.05%

ROCE

10Y Avg-10.72%
5Y Avg-8.02%
3Y Avg-12.08%
Latest-8.62%

Peer Comparison

Pharmaceutical Commercialization
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
VEEVVeeva Systems Inc.35.99B218.9550.6816.2%27.93%12.22%2.97%0.01
OPRXOptimizeRx Corporation234.87M12.60-11.4528.81%0.03%0.03%2.03%0.28

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+7.22M7.75M12.13M21.21M24.6M43.31M61.29M62.45M71.52M92.13M
Revenue Growth %0.11%0.07%0.56%0.75%0.16%0.76%0.42%0.02%0.15%0.29%
Cost of Goods Sold+3.62M3.41M6.17M9M9.16M19.21M25.65M23.48M28.62M32.75M
COGS % of Revenue0.5%0.44%0.51%0.42%0.37%0.44%0.42%0.38%0.4%0.36%
Gross Profit+3.6M4.34M5.95M12.21M15.44M24.11M35.64M38.97M42.9M59.38M
Gross Margin %0.5%0.56%0.49%0.58%0.63%0.56%0.58%0.62%0.6%0.64%
Gross Profit Growth %0.1%0.21%0.37%1.05%0.26%0.56%0.48%0.09%0.1%0.38%
Operating Expenses+4.2M5.87M8.08M12.03M19.13M26.24M35.28M51.26M69.3M73.08M
OpEx % of Revenue0.58%0.76%0.67%0.57%0.78%0.61%0.58%0.82%0.97%0.79%
Selling, General & Admin3.32M5.24M6.75M10.29M14.36M19.93M33.19M49.24M58.02M61.27M
SG&A % of Revenue0.46%0.68%0.56%0.49%0.58%0.46%0.54%0.79%0.81%0.67%
Research & Development290.37K398.4K1.01M675.66K1.6M00000
R&D % of Revenue0.04%0.05%0.08%0.03%0.07%-----
Other Operating Expenses583.95K235.28K324.55K449K3.16M6.31M2.09M2.02M11.28M11.82M
Operating Income+-597.41K-1.58M-2.13M180.13K-3.69M-2.14M361.1K-12.29M-26.4M-13.71M
Operating Margin %-0.08%-0.2%-0.18%0.01%-0.15%-0.05%0.01%-0.2%-0.37%-0.15%
Operating Income Growth %0.42%-1.65%-0.35%1.08%-21.5%0.42%1.17%-35.04%-1.15%0.48%
EBITDA+-263.46K-1.35M-1.81M496.63K-2.52M-164.24K2.33M-10.27M-24M-9.38M
EBITDA Margin %-0.04%-0.17%-0.15%0.02%-0.1%-0%0.04%-0.16%-0.34%-0.1%
EBITDA Growth %0.65%-4.11%-0.34%1.28%-6.07%0.93%15.17%-5.41%-1.34%0.61%
D&A (Non-Cash Add-back)333.95K235.28K324.55K316.5K1.18M1.97M1.97M2.02M2.4M4.33M
EBIT-595.14K-1.54M-2.13M787.8K-2.69M-1.32M361.1K-11.44M-23.71M-13.22M
Net Interest Income+2.27K42.31K25.94K46.21K288.03K68.58K16.98K852.3K738K-5.83M
Interest Income2.27K42.31K25.94K46.21K288.03K68.58K16.98K852.3K2.19M329K
Interest Expense000000001.45M6.16M
Other Income/Expense2.27K42.31K25.94K46.21K1.45M-71.81K16.98K852.3K1.24M-5.68M
Pretax Income+-595.14K-1.54M-2.1M226.34K-2.24M-2.21M378.08K-11.44M-25.16M-19.39M
Pretax Margin %-0.08%-0.2%-0.17%0.01%-0.09%-0.05%0.01%-0.18%-0.35%-0.21%
Income Tax+2.27K000897.96K000-7.6M725K
Effective Tax Rate %1%1%1%1%1.4%1%1%1%0.7%1.04%
Net Income+-595.14K-1.54M-2.1M226.34K-3.14M-2.21M378.08K-11.44M-17.57M-20.11M
Net Margin %-0.08%-0.2%-0.17%0.01%-0.13%-0.05%0.01%-0.18%-0.25%-0.22%
Net Income Growth %0.42%-1.59%-0.37%1.11%-14.88%0.3%1.17%-31.25%-0.54%-0.14%
Net Income (Continuing)-595.14K-1.54M-2.1M226.34K-3.14M-2.21M378.08K-11.44M-17.57M-20.11M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-0.07-0.16-0.210.02-0.23-0.150.02-0.64-1.03-1.10
EPS Growth %0.48%-1.2%-0.31%1.09%-13.04%0.35%1.14%-30.91%-0.61%-0.07%
EPS (Basic)-0.07-0.16-0.210.02-0.23-0.150.02-0.64-1.03-1.10
Diluted Shares Outstanding8.19M9.9M9.82M11.86M13.39M14.83M17.69M17.78M17.12M18.29M
Basic Shares Outstanding8.19M9.9M9.82M11.32M13.39M14.83M17.23M17.78M17.12M18.29M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+11.13M10.18M8.81M15.96M27.14M32.86M115.11M98.58M54.33M53.97M
Cash & Short-Term Investments8.21M7.03M5.12M8.91M18.85M10.52M84.68M74.14M13.85M13.38M
Cash Only8.21M7.03M5.12M8.91M18.85M10.52M84.68M18.21M13.85M13.38M
Short-Term Investments000000055.93M00
Accounts Receivable2.85M3.06M3.43M6.46M7.42M17.89M24.8M22.16M37.29M38.21M
Days Sales Outstanding143.94144.11103.26111.15110.07150.72147.69129.49190.3151.39
Inventory0000000000
Days Inventory Outstanding----------
Other Current Assets000000608.15K473.65K404.47K387K
Total Non-Current Assets+1.19M1.3M954.85K9.09M29.5M27.47M25.87M36.07M129.04M117.2M
Property, Plant & Equipment10.24K173.65K167.31K149.33K735.88K594.83K472.64K372.77K722.3K516K
Fixed Asset Turnover705.21x44.64x72.49x142.01x33.43x72.82x129.68x167.53x99.02x178.54x
Goodwill0003.68M14.74M14.74M14.74M22.67M78.36M70.87M
Intangible Assets1.17M1.12M782.5K5.26M13.94M12.12M10.65M13.02M49.4M45.52M
Long-Term Investments0000000000
Other Non-Current Assets5.05K5.05K5.05K5.05K80.73K12.86K12.86K5.05K568.05K296K
Total Assets+12.31M11.48M9.76M25.05M56.64M60.33M140.99M134.65M183.37M171.17M
Asset Turnover0.59x0.68x1.24x0.85x0.43x0.72x0.43x0.46x0.39x0.54x
Asset Growth %0.75%-0.07%-0.15%1.57%1.26%0.07%1.34%-0.04%0.36%-0.07%
Total Current Liabilities+3.37M3.67M3.54M4.23M6.11M10.03M9.37M8.4M17.88M18.65M
Accounts Payable3.14M369.21K457.29K411.01K493K618.25K606.81K1.55M2.23M2.16M
Days Payables Outstanding316.1939.527.0316.6719.6511.758.6324.0928.424.03
Short-Term Debt000000002M2M
Deferred Revenue (Current)227K386.58K507.16K610.63K580.01K285.8K1000K164.31K171.84K473K
Other Current Liabilities0001.91M00005.55M0
Current Ratio3.30x2.78x2.49x3.77x4.44x3.28x12.29x11.74x3.04x2.89x
Quick Ratio3.30x2.78x2.49x3.77x4.44x3.28x12.29x11.74x3.04x2.89x
Cash Conversion Cycle----------
Total Non-Current Liabilities+02.91M2.58M2.37M5.67M325.53K236.73K144.53K38.94M35.52M
Long-Term Debt0000000034.23M30.82M
Capital Lease Obligations0000448.75K325.53K236.73K144.53K371.44K209K
Deferred Tax Liabilities000000004.34M4.49M
Other Non-Current Liabilities0002.37M5.22M00000
Total Liabilities3.37M3.67M3.54M6.6M11.78M10.35M9.61M8.54M56.82M54.17M
Total Debt+0000564.18K448.75K327.71K234.43K36.82M33.19M
Net Debt-8.21M-7.03M-5.12M-8.91M-18.29M-10.07M-84.35M-17.97M22.97M19.81M
Debt / Equity----0.01x0.01x0.00x0.00x0.29x0.28x
Debt / EBITDA------0.14x---
Net Debt / EBITDA----17.95x---36.26x---
Interest Coverage---------18.16x-2.23x
Total Equity+8.94M7.81M6.22M18.46M44.86M49.97M131.38M126.11M126.55M117M
Equity Growth %0.94%-0.13%-0.2%1.97%1.43%0.11%1.63%-0.04%0%-0.08%
Book Value per Share1.090.790.631.563.353.377.437.097.396.40
Total Shareholders' Equity8.94M7.81M6.22M18.46M44.86M49.97M131.38M126.11M126.55M117M
Common Stock29.03K29.72K29.32K12.04K14.6K15.22K17.86K18.29K19.9K20K
Retained Earnings-26.72M-28.26M-30.36M-30.28M-33.42M-35.63M-35.25M-46.69M-64.26M-84.37M
Treasury Stock0000000-1.21K-1.74K-2K
Accumulated OCI-22.41K-25.69K-74.28K-104.7K000000
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+515.11K-465.96K-1.48M792.55K-1.66M-6.31M726.04K10.65M-7.24M4.89M
Operating CF Margin %0.07%-0.06%-0.12%0.04%-0.07%-0.15%0.01%0.17%-0.1%0.05%
Operating CF Growth %10.14%-1.9%-2.18%1.54%-3.1%-2.8%1.12%13.67%-1.68%1.68%
Net Income-595.14K-1.54M-2.1M226.34K-3.14M-2.21M378.08K-11.44M-17.57M-20.11M
Depreciation & Amortization333.95K235.28K324.55K316.5K1.28M2.08M1.97M2.02M2.4M4.33M
Stock-Based Compensation327.75K175.18K87.38K1.86M2.26M3.17M5.49M15.75M13.72M11.47M
Deferred Taxes31.73K065.74K2.4K-897.96K200K0001.45M
Other Non-Cash Items253.36K384.13K815.01K656.93K635K140.39K80K363.51K9.76M6.83M
Working Capital Changes163.46K278.65K-668.48K-2.27M-1.8M-9.69M-7.19M3.96M-15.55M921K
Change in Receivables-747.07K-212.95K-370.49K-2.79M-548.83K-10.67M-6.99M2.28M-8.71M-2.17M
Change in Inventory-61.01K271.09K491.07K-93.22K-882.48K-2.21M0000
Change in Payables864.67K60.93K-909.64K647.49K-336.43K3.48M-603.09K555.39K195K-72K
Cash from Investing+-100.96K-349.54K-42.24K-5.69M-10.58M-124.72K-486K-58.18M-25.34M-450K
Capital Expenditures-100.96K-349.54K-42.24K-91.01K-1.59M-68.04K-100.32K-81K-87K-112K
CapEx % of Revenue0.01%0.05%0%0%0.06%0%0%0%0%0%
Acquisitions----------
Investments----------
Other Investing-98.92K-171.1K0-56.65K0-56.68K-385.68K-163.56K-774K-338K
Cash from Financing+4.35M-357.42K-390K8.69M22.18M-1.9M73.92M-18.95M28.22M-4.91M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid0000000000
Share Repurchases----------
Other Financing000521.26K877.7K-4.39M3.25M1.07M-278K0
Net Change in Cash----------
Free Cash Flow+414.15K-815.5K-1.52M701.54K-3.25M-6.44M240.04K10.41M-8.11M4.78M
FCF Margin %0.06%-0.11%-0.13%0.03%-0.13%-0.15%0%0.17%-0.11%0.05%
FCF Growth %1.89%-2.97%-0.87%1.46%-5.63%-0.98%1.04%42.37%-1.78%1.59%
FCF per Share0.05-0.08-0.160.06-0.24-0.430.010.59-0.470.26
FCF Conversion (FCF/Net Income)-0.87x0.30x0.70x3.50x0.53x2.86x1.92x-0.93x0.41x-0.24x
Interest Paid000000001.21M6.2M
Taxes Paid0000000048K161K

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-8.78%-18.37%-29.99%1.83%-9.93%-4.65%0.42%-8.88%-13.9%-16.51%
Return on Invested Capital (ROIC)-47.21%-156.85%-170.35%2.54%-15.34%-4.82%0.62%-11.88%-15.37%-7.18%
Gross Margin49.84%55.99%49.09%57.56%62.77%55.65%58.14%62.4%59.98%64.45%
Net Margin-8.24%-19.86%-17.35%1.07%-12.78%-5.1%0.62%-18.32%-24.56%-21.83%
Debt / Equity----0.01x0.01x0.00x0.00x0.29x0.28x
Interest Coverage---------18.16x-2.23x
FCF Conversion-0.87x0.30x0.70x3.50x0.53x2.86x1.92x-0.93x0.41x-0.24x
Revenue Growth11.04%7.35%56.45%74.86%15.99%76.08%41.51%1.89%14.53%28.81%

Frequently Asked Questions

Growth & Financials

OptimizeRx Corporation (OPRX) reported $109.5M in revenue for fiscal year 2024. This represents a 9752% increase from $1.1M in 2011.

OptimizeRx Corporation (OPRX) grew revenue by 28.8% over the past year. This is strong growth.

Yes, OptimizeRx Corporation (OPRX) is profitable, generating $0.0M in net income for fiscal year 2024 (-21.8% net margin).

Dividend & Returns

OptimizeRx Corporation (OPRX) has a return on equity (ROE) of -16.5%. Negative ROE indicates the company is unprofitable.

OptimizeRx Corporation (OPRX) generated $11.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.